---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-267038"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:13:05.717009+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharma Q3 rev $148.4M (+17% YoY); raises FY25 revenue guidance to $565-$585M

## Summary
- GAAP net income $52.8M ($0.42 diluted EPS); non-GAAP net income $86.1M ($0.68 diluted EPS).
- FIRDAPSE net revenue $92.2M (+16.2% YoY); AGAMREE net revenue $32.4M (+115.2% YoY).
- FYCOMPA net revenue $23.8M (-25.8% YoY) as first generic tablet entered market in Q2 2025.
- Cash and equivalents $689.9M as of Sep 30, 2025; $200M share repurchase program announced.
- Full-year AGAMREE guidance raised to $105-$115M; FYCOMPA guidance raised to $100-$110M.

## SEC filing metadata
- accession: 0001193125-25-267038
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525267038/0001193125-25-267038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525267038/d56925d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-267038
- JSON: https://secwatch.observer/filing/0001193125-25-267038.json
- Plain text: https://secwatch.observer/filing/0001193125-25-267038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.